Ardelyx Inc ((ARDX)) has held its Q2 earnings call. Read on for the main highlights of the call.

Summer Sale - Claim 70% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Ardelyx Inc.’s latest earnings call mixed strong commercial momentum with clear caution, as record revenue and narrowing losses were offset by payer-access hurdles and lowered near-term guidance. Management highlighted robust demand for IBSRELA and growing traction for XPHOZAH, while acknowledging that tighter insurance controls are slowing new patient starts and clouding visibility, especially for the dialysis-focused franchise.

Record Quarterly Revenue

Ardelyx reported total product revenue of $118.0 million for Q2 2026, a 31% year-over-year increase and the largest quarterly haul in the company’s history. The performance underscores rising adoption of its marketed therapies despite access challenges, and positions the company as a more meaningful revenue story in the specialty pharma space.

IBSRELA Strong Growth

IBSRELA delivered $86.2 million in Q2 2026 revenue, up 33% from the prior year with management calling it the highest-demand quarter so far. Physician adoption continues to build, supporting the company’s belief that IBSRELA can ultimately scale toward a blockbuster opportunity even as payers tighten controls.

XPHOZAH Momentum

XPHOZAH generated $31.9 million in Q2 2026 revenue, a 27% year-over-year increase as total dispenses climbed 33% and paid prescriptions rose 25%. The company also reported the highest number of prescribers and prescriptions per writer since early 2025, signaling deepening engagement among dialysis providers.

Improving Profitability Trend

Net loss narrowed to $16.7 million in Q2 2026 from $19.1 million a year ago, even as Ardelyx spent more to support growth and its pipeline. Management reiterated its expectation to turn income positive in 2027, framing current investments as necessary groundwork for sustainable profitability.

Strengthened Commercial Capabilities

To drive adoption, Ardelyx has doubled its field reimbursement team in the first half of 2026 and expanded its sales force to 144 representatives. These moves are aimed at boosting provider engagement and helping practices navigate payer requirements, particularly for IBSRELA.

Patient Access and Fulfillment Initiatives

The company’s IBSRELA Pharmacy Network and field reimbursement deployment are showing tangible results in fulfillment metrics. Prescriptions routed through the network are filled faster, see higher completion rates, and on average generate about one extra refill per patient each year, improving recurring revenue.

Solid Balance Sheet and Liquidity

Ardelyx ended the quarter with $281.8 million in cash, cash equivalents and short-term investments, providing ample resources to fund operations and growth plans. The company also drew $50 million from its SLR financing arrangement, adding further flexibility to navigate market and regulatory shifts.

Pipeline and IP Position

Beyond its marketed products, Ardelyx is advancing tenapanor in the ACCEL Phase III trial for chronic idiopathic constipation with enrollment on track. Management emphasized a growing patent estate anchored by the ’299 patent, suggesting potential intellectual property runway that could extend well into the next decade.

Disciplined Cost Management and Updated OPEX Target

The company revised its 2026 operating expense guidance to below $500 million, signaling tighter cost control following the revenue outlook update. Management framed this as disciplined spending rather than retrenchment, aiming to balance commercialization, pipeline investment and the path to profitability.

Access Barriers Impacting New Patient Starts

Payers have introduced more step edits and stricter prior authorization requirements, which Ardelyx says are delaying new patient starts for IBSRELA. While these measures are not blocking access outright, they are meaningful enough to temper near-term growth expectations and demand more resources.

Lowered IBSRELA Full-Year Guidance

Reflecting these access headwinds, Ardelyx cut its 2026 IBSRELA revenue guidance to a range of $350 million to $370 million. Even at the midpoint the company still expects more than 30% annual growth, but investors will note that the trajectory is now less steep than previously envisioned.

Pulled Longer-Term XPHOZAH Target

Management withdrew its prior long-range $750 million revenue target for XPHOZAH, opting to reassess the dialysis market landscape. The move, tied to reimbursement shifts and upcoming quality and payment rules, introduces added uncertainty around the franchise’s medium-term scaling potential.

Higher Operating Expenses Year-over-Year

Operating costs climbed as R&D rose to $26.1 million from $15.7 million and SG&A to $101.4 million from $84.0 million versus Q2 2025. The increases largely reflect the ACCEL trial and expanded commercial efforts, underscoring the investment required to overcome access hurdles and support growth.

Legal Outcome on CMS Litigation

The D.C. Circuit Court of Appeals affirmed dismissal of Ardelyx’s lawsuit against the Centers for Medicare & Medicaid Services. With oral-only phosphate-lowering drugs remaining within the payment bundle, the company said it will not pursue further litigation on that specific reimbursement issue.

Potential Competitive and IP Pressure

Management acknowledged that strong growth in IBSRELA and XPHOZAH is likely to attract interest from generic challengers over time. While Ardelyx is building a robust intellectual property estate, it has not yet quantified potential future legal challenges, leaving some competitive risk unmodeled.

Reduced Near-Term Visibility for XPHOZAH

The end of temporary add-on payments, possible changes to dialysis quality measures and evolving responses from dialysis organizations are all clouding short-term XPHOZAH visibility. As a result, Ardelyx is taking a more cautious stance on near-term revenue expectations for the product.

Forward-Looking Guidance and Outlook

Ardelyx now expects 2026 IBSRELA revenue of $350 million to $370 million, with about 60% of sales in the second half and the fourth quarter as the strongest. XPHOZAH guidance is maintained at $110 million to $120 million, operating expenses are guided below $500 million, and management continues to chart a path to profitability in 2027.

The earnings call painted Ardelyx as a growth story facing real but manageable payer and reimbursement challenges. Record revenue, strong product demand and solid liquidity support a constructive medium-term view, but investors will watch closely how access initiatives, cost discipline and market dynamics play out against the company’s ambitious long-term expectations.